KPTI - カリョファ―ム・セラピュ―ティクス (Karyopharm Therapeutics Inc.) カリョファ―ム・セラピュ―ティクス

 KPTIのチャート


 KPTIの企業情報

symbol KPTI
会社名 Karyopharm Therapeutics Inc (カリョファ―ム・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 カリオファーム・セラピューティクス(Karyopharm Therapeutics Inc.)は臨床段階の製薬会社である。同社はその他の主要疾患と癌の治療用核輸送と関連ターゲットに対する薬物の発見・開発・商業化に焦点を当てる。同社は核輸出タンパク質XPO1を阻害する化合物、核輸出の選択的阻害剤(SINE)及び小分子を発見・開発する。同社の薬物候補であるセリネクサー(KPT-330)は前処理再発性のがん徴候の治療のための経口投与剤である。同社はまた固形腫瘍適応症におけるセリクソーの臨床開発に従事する。口腔セリソクサーは再発性・難治性血液学と固形腫瘍の悪性腫瘍患者に行われる複数の後期臨床試験で評価される。リード薬候補である口腔セリソクサー(KPT-330)、verdinexor(KPT-335)、KPT-8602およびKPT-9274は臨床開発中である。   カリョファ―ム・セラピュ―ティクスは米国の製薬会社。がんや他の主要疾患の新治療薬の発見・開発に従事。主な製品候補には、臨床段階の多発性骨髄腫治療薬「セリネクソ―ル」がある。また、白血病などの治療薬候補も保有。同社は2008年に設立し、マサチュ―セッツ州に本社を置く。   
本社所在地 85 Wells Avenue 2nd Floor Newton MA 02459 USA
代表者氏名 Sharon Shacham シャロン・シャチャム
代表者役職名 President Co-Founder Chief Scientific Officer
電話番号 +1 617-658-0600
設立年月日 39783
市場名 NASDAQ National Market System
ipoyear 2013年
従業員数 154人
url www.karyopharm.com
nasdaq_url https://www.nasdaq.com/symbol/kpti
adr_tso
EBITDA EBITDA(百万ドル) -143.07800
終値(lastsale) 15.55
時価総額(marketcap) 941761631.95
時価総額 時価総額(百万ドル) 743.11350
売上高 売上高(百万ドル) 31.42500
企業価値(EV) 企業価値(EV)(百万ドル) 501.99250
当期純利益 当期純利益(百万ドル) -141.79400
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Karyopharm Therapeutics Inc revenues increased from $71K to $29.9M. Net loss increased 22% to $72.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and Development increase of 82% to $86.1M (expense) General and Administrative increase of 33% to $17.1M (expense).

 KPTIのテクニカル分析


 KPTIのニュース

   Expanded Partnership with Medidata Supports Karyopharm’s Mission to Develop First-in-Class Therapeutics  2021/03/10 14:00:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Karyopharm expands partnership with Medidata by adopting additional technology solutions to help develop therapeutics for cancer and other diseases.
   2 Long-Term Bargains Emerge in Biotech  2021/03/08 15:00:00 The Street RealMoney
Karyopharm Therapeutics (KPTI) and Gamida Cell (GMDA) are two long-term bargains in biotech, according to Bret Jensen, who notes that the promising companies have seen their shares pull back significantly in recent weeks….XBI
   The Daily Biotech Pulse: Fulgent's Big Quarter, Gilead Awaits FDA Decision, Apellis Winds Up COVID-19 Study  2021/03/05 13:15:09 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 4) AtriCure, Inc. (NASDAQ: ATRC ) Five Prime Therapeutics, Inc. ( NASDAQ: FPRX) - announced a deal to be bought by Amgen Inc. (NASDAQ: AMGN ) for $1.9 billion Down In The Dumps (Biotech Stocks Hitting 52-week Lows March 4) AbCellera Biologics Inc. (NASDAQ: ABCL ) Acutus Medical, Inc. (NASDAQ: AFIB ) ADC Therapeutics SA (NYSE: ADCT ) Aptose Biosciences Inc. (NASDAQ: APTO ) Assembly Biosciences, Inc. (NASDAQ: ASMB ) Athenex, Inc. (NASDAQ: ATNX ) Biophytis SA (NASDAQ: BPTS ) Bioventus Inc. (NASDAQ: BVS ) Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI ) BriaCell Therapeutics Corp. (NASDAQ: BCTX ) Decibel Therapeutics, Inc. (NASDAQ: DBTX ) Dyne Therapeutics, Inc. (NASDAQ: DYN ) (reacted to fourth-quarter results) Epizyme, Inc. (NASDAQ: EPZM ) Freeline Therapeutics Holdings plc (NASDAQ: FRLN ) Galecto, Inc. (NASDAQ: GLTO ) Inhibikase Therapeutics, Inc.
   KARYOPHARM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Karyopharm Therapeutics Inc. - KPTI | MarketScreener  2021/02/13 03:51:03 MarketScreener
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC , announces that KSF has commenced an investigation into Karyopharm… | February 13, 2021
   KARYOPHARM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Karyopharm Therapeutics Inc. - KPTI - Stocks News Feed  2021/02/13 03:50:00 Stocks News Feed
NEW ORLEANS–(BUSINESS WIRE)–Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Karyopharm Therapeutics Inc. (NasdaqGS: KPTI). On February 22, 2019, the Federal Drug Administration (“FDA”) reported serious flaws in the New Drug Application… Read More »KARYOPHARM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Karyopharm Therapeutics Inc. – KPTI
   Expanded Partnership with Medidata Supports Karyopharm’s Mission to Develop First-in-Class Therapeutics  2021/03/10 14:00:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Karyopharm expands partnership with Medidata by adopting additional technology solutions to help develop therapeutics for cancer and other diseases.
   2 Long-Term Bargains Emerge in Biotech  2021/03/08 15:00:00 The Street RealMoney
Karyopharm Therapeutics (KPTI) and Gamida Cell (GMDA) are two long-term bargains in biotech, according to Bret Jensen, who notes that the promising companies have seen their shares pull back significantly in recent weeks….XBI
   The Daily Biotech Pulse: Fulgent's Big Quarter, Gilead Awaits FDA Decision, Apellis Winds Up COVID-19 Study  2021/03/05 13:15:09 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 4) AtriCure, Inc. (NASDAQ: ATRC ) Five Prime Therapeutics, Inc. ( NASDAQ: FPRX) - announced a deal to be bought by Amgen Inc. (NASDAQ: AMGN ) for $1.9 billion Down In The Dumps (Biotech Stocks Hitting 52-week Lows March 4) AbCellera Biologics Inc. (NASDAQ: ABCL ) Acutus Medical, Inc. (NASDAQ: AFIB ) ADC Therapeutics SA (NYSE: ADCT ) Aptose Biosciences Inc. (NASDAQ: APTO ) Assembly Biosciences, Inc. (NASDAQ: ASMB ) Athenex, Inc. (NASDAQ: ATNX ) Biophytis SA (NASDAQ: BPTS ) Bioventus Inc. (NASDAQ: BVS ) Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI ) BriaCell Therapeutics Corp. (NASDAQ: BCTX ) Decibel Therapeutics, Inc. (NASDAQ: DBTX ) Dyne Therapeutics, Inc. (NASDAQ: DYN ) (reacted to fourth-quarter results) Epizyme, Inc. (NASDAQ: EPZM ) Freeline Therapeutics Holdings plc (NASDAQ: FRLN ) Galecto, Inc. (NASDAQ: GLTO ) Inhibikase Therapeutics, Inc.
   KARYOPHARM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Karyopharm Therapeutics Inc. - KPTI | MarketScreener  2021/02/13 03:51:03 MarketScreener
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC , announces that KSF has commenced an investigation into Karyopharm… | February 13, 2021
   KARYOPHARM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Karyopharm Therapeutics Inc. - KPTI - Stocks News Feed  2021/02/13 03:50:00 Stocks News Feed
NEW ORLEANS–(BUSINESS WIRE)–Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Karyopharm Therapeutics Inc. (NasdaqGS: KPTI). On February 22, 2019, the Federal Drug Administration (“FDA”) reported serious flaws in the New Drug Application… Read More »KARYOPHARM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Karyopharm Therapeutics Inc. – KPTI
   KARYOPHARM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Karyopharm Therapeutics Inc. - KPTI | MarketScreener  2021/02/13 03:51:03 MarketScreener
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC , announces that KSF has commenced an investigation into Karyopharm… | February 13, 2021
   KARYOPHARM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Karyopharm Therapeutics Inc. - KPTI - Stocks News Feed  2021/02/13 03:50:00 Stocks News Feed
NEW ORLEANS–(BUSINESS WIRE)–Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Karyopharm Therapeutics Inc. (NasdaqGS: KPTI). On February 22, 2019, the Federal Drug Administration (“FDA”) reported serious flaws in the New Drug Application… Read More »KARYOPHARM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Karyopharm Therapeutics Inc. – KPTI
   Leerink Partners Stick to Their Buy Rating for Karyopharm Therapeutics By Investing.com  2021/02/11 20:25:00 Investing.com
Leerink Partners Stick to Their Buy Rating for Karyopharm Therapeutics
   Karyopharm Therapeutics: 4Q Earnings Snapshot  2021/02/11 12:39:35 San Francisco Chronicle
NEWTON, Mass. (AP) _ Karyopharm Therapeutics Inc. (KPTI) on Thursday reported a loss of…
   Earnings Scheduled For February 11, 2021  2021/02/11 08:51:42 Benzinga
Companies Reporting Before The Bell • Bluerock Residential Growth REIT, Inc. Class A Common Stock (AMEX: BRG ) is expected to report quarterly loss at $0.55 per share on revenue of $54.86 million. • AllianceBernstein Holding (NYSE: AB ) is expected to report quarterly earnings at $0.81 per share on revenue of $805.56 million. • Applied Genetic (NASDAQ: AGTC ) is likely to report earnings for its second quarter. • Alnylam Pharmaceuticals (NASDAQ: ALNY ) is projected to report quarterly loss at $1.76 per share on revenue of $146.07 million. • Alithya Group (NASDAQ: ALYA ) is expected to report earnings for its third quarter. • AstraZeneca (NASDAQ: AZN ) is likely to report quarterly earnings at $0.68 per share on revenue of $6.97 billion. • Coca-Cola European (NYSE: CCEP ) is expected to report earnings for its fourth quarter. • Cohu (NASDAQ: COHU ) is expected to report quarterly earnings at $0.61 per share on revenue of $197.76 million. • CSP (NASDAQ: CSPI ) is estimated to report earnings for its first quarter.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 カリョファ―ム・セラピュ―ティクス KPTI Karyopharm Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)